MedTrace Logo

Safety Study of Dexmedetomidine in Elderly Under General Anesthesia

NCT05567523 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-10-13

No results posted yet for this study

Summary

The purpose of this study is to find out appropriate dose range of dexmedetomidine to provide the elderly patients satisfactory sedation and analgesia with stable hemodynamics during perioperative period of hip replacement under general anesthesia.

Conditions

  • Hip Fractures
  • Hip Disease

Interventions

DRUG

Dexmedetomidine

In dexmedetomidine groups, patients will be pumped 0.1ml/kg of dexmedetomidine (contained dexmedetomidine 0.25/0.5/0.75µg/kg in Group D0.25/D0.5/D0.75) for 15min before anesthesia induction, following continuous infusion at the rate of 0.125ml/kg/h until the end of operation.

DRUG

Normal saline

normal saline

DRUG

Midazolam

midazolam

Sponsors & Collaborators

  • Zhenjiang First People's Hospital

    lead OTHER

Principal Investigators

  • Haitong Liu · Zhenjiang First People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2022-02-28
Completion
2022-03-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05567523 on ClinicalTrials.gov